论文部分内容阅读
目的探讨头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗呼吸道重症感染疾病的临床疗效。方法选取在我院就诊的呼吸道重症感染疾病患者88例,随机分为对照组和治疗组,每组44例。对照组患者采用头孢哌酮钠舒巴坦钠治疗;治疗组患者采用头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗。比较两组患者疗效。结果治疗组患者总有效率为90.9%,明显优于对照组的70.5%;两组患者治疗后血气分数改善幅度明显优于治疗前,且治疗组患者治疗后血气分数改善幅度明显优于对照组;治疗组患者呼吸道重症感染细菌检查结果转阴时间、症状消失时间、治疗总时间明显短于对照组;对照组患者治疗期间有2例出现不良反应,治疗组有7例患者出现不良反应;差异均有统计学意义(均P<0.05)。结论头孢哌酮钠舒巴坦钠联合左氧氟沙星治疗呼吸道重症感染疾病临床疗效明显,且安全性高。
Objective To investigate the clinical efficacy of cefoperazone sodium and sulbactam combined with levofloxacin in the treatment of severe respiratory infections. Methods Eighty-eight patients with severe respiratory infections in our hospital were randomly divided into control group and treatment group, 44 cases in each group. Patients in the control group were treated with cefoperazone sodium and sulbactam sodium; patients in the treatment group were treated with cefoperazone sodium and sulbactam sodium combined with levofloxacin. Compare the efficacy of two groups of patients. Results The total effective rate of the treatment group was 90.9%, which was significantly better than that of the control group (70.5%). The improvement of blood gas score of the two groups was obviously better than that before treatment, and the improvement of blood gas score of the treatment group was obviously better than that of the control group ; Treatment group patients with severe respiratory tract infection bacterial test results negative time, symptoms disappear time, the total treatment time was significantly shorter than the control group; patients in the control group during the treatment of adverse reactions in 2 cases, 7 patients in the treatment group showed adverse reactions; differences All were statistically significant (P <0.05). Conclusion Cefoperazone sodium and sulbactam sodium combined with levofloxacin in the treatment of severe respiratory diseases have obvious clinical efficacy and safety.